This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

C. HUNTER MONTGOMERY, M.D.; JOHN M. KNOX, M.D.; GEORGE W. SCIPLE, M.D.; E. M. VANDER STOEP, M.D.

Arch Intern Med. 1961;107(5):732-735.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

While the treponemicidal properties of erythromycin were first described in 1953 by Keller and Morton,¹ it is only recently that adequate clinical information has become available. Keller and Morton, as well as Turner and Schaeffer,² were able to demonstrate Treponema pallidum more susceptible to the action of erythromycin than other antibiotics with the exception of penicillin. Later, Kolmer³ reported similar treponemicidal properties to erythromycin but obtained superior results with several other antibiotics. In 1954 Alexander and Schoch⁴ treated 4 patients with syphilitic lesions with erythromycin and observed rapid disappearance of Treponema pallidum from the lesions. In 1956 Montero⁵ presented 27 patients with early syphilis treated with a total of 9 to 12 gm. of erythromycin with satisfactory results. In 1959 Montgomery and Knox⁶ reported on 40 darkfield-positive cases of early syphilis treated with 9 to 10 gm. of erythromycin stearate over a period of . . . [Full Text PDF of this Article]

Author Affiliations
HOUSTON, TEX.

Clinical Instructor of Medicine (Dr. Montgomery), and Associate Professor of Dermatology (Dr. Knox), Baylor University College of Medicine; Senior Assistant Surgeon, United States Public Health Service, Savannah, Ga. (Dr. Sciple); Senior Assistant Surgeon, United States Public Health Service, Houston, Tex. (Dr. Vander Stoep).

Footnotes
Submitted for publication April 28, 1960.

Supported by grants from Abbott Laboratories, North Chicago, Ill., and Eli Lilly and Company, Indianapolis.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?